Niagen Biosciences Announces Findings from First Randomized Trial of Niagen NR for Long COVID
Study Overview: Niagen Biosciences conducted a randomized controlled trial on its nicotinamide riboside (NR) supplement, Niagen, to evaluate its effects on individuals suffering from long COVID symptoms, with 58 participants receiving either the supplement or a placebo.
Results and Findings: While the primary endpoint was not statistically significant, participants taking Niagen NR reported improvements in fatigue, sleep quality, and mood, with NAD+ levels increasing significantly, indicating potential benefits in addressing long COVID.
Safety and Tolerability: The Niagen NR supplement was well tolerated among participants, showing no significant difference in adverse events compared to the placebo group, suggesting a favorable safety profile.
Future Research Plans: Niagen Biosciences aims to further investigate NAD+ biology and its therapeutic potential for post-viral recovery, with plans for larger studies to validate the initial findings from this trial.
Trade with 70% Backtested Accuracy
Analyst Views on NAGE
About NAGE
About the author
Doseology Sciences Acquires Feed That Brain for $400,000, Expanding into Performance Wellness Market
- Strategic Acquisition: Doseology Sciences acquired the Feed That Brain brand for $400,000, marking a strategic expansion into the performance wellness segment, which is expected to accelerate the Canadian launch of next-generation clean energy pouches.
- Executive Appointment: Concurrently, the company appointed Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units, aiming to leverage his extensive experience in retail and brand building to drive business growth.
- Market Potential: According to Grand View Research, the global energy drinks market is projected to grow from $79.4 billion in 2024 to $125.1 billion by 2030, while the nicotine pouch category is expected to expand from $5.4 billion to over $25 billion at a 29.6% CAGR, indicating strong growth potential for Doseology's market positioning.
- Product Innovation: Doseology's U.S. subsidiary is developing pouch-based offerings that blend caffeine, nootropics, and adaptogens, designed to provide sugar-free, smoke-free alternatives for professionals and wellness consumers seeking functional stimulation, further solidifying its competitive edge in the health tech sector.
Niagen Bioscience Introduces Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. with Patented Niagen® (Nicotinamide Riboside)
Launch of Tru Niagen® Beauty: Niagen Bioscience has introduced Tru Niagen® Beauty, the first beauty supplement in the U.S. featuring Niagen (nicotinamide riboside), aimed at enhancing skin, hair, and nail health through cellular support.
Key Ingredients and Benefits: The supplement contains a blend of clinically studied ingredients, including Astaxanthin, Hyaluronic Acid, Grape Seed Extract, Biotin, and Vitamin E, designed to improve skin hydration, elasticity, and overall beauty from within.
Market Growth Potential: The U.S. astaxanthin market is projected to grow significantly, reflecting increasing consumer demand for natural antioxidants and health supplements, while the global nutricosmetics market is also expected to expand rapidly.
Commitment to Scientific Research: Niagen Bioscience emphasizes its dedication to advancing healthspan through evidence-based innovations and rigorous scientific research, positioning itself as a leader in NAD+ science and healthy aging.
